← Back to Search

Microbiome Therapy

Fecal filtrate from 150 g stool from healthy lean donors for Insulin Resistance

Phase 2
Waitlist Available
Led By Johane P Allard, MD
Research Sponsored by Johane Allard
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 3 month
Awards & highlights

Study Summary

This study is evaluating whether a treatment that transfers stool from healthy people into obese people can improve blood sugar control and weight.

Eligible Conditions
  • Insulin Resistance
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 3 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 3 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Insulin Resistance compared to baseline
Secondary outcome measures
Anxiety score
Appetite score
Body mass index
+4 more
Other outcome measures
Blood lipid profile
C-reactive protein
Change in food intake
+13 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Allogenic treatment groupExperimental Treatment1 Intervention
Fecal filtrate from 150 g stool from healthy lean donors
Group II: Autologous control groupPlacebo Group1 Intervention
Fecal filtrate from 150 g of the recipient's own stool

Find a Location

Who is running the clinical trial?

Johane AllardLead Sponsor
9 Previous Clinical Trials
887 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,344 Previous Clinical Trials
26,453,369 Total Patients Enrolled
10 Trials studying Insulin Resistance
1,413 Patients Enrolled for Insulin Resistance
MOUNT SINAI HOSPITALOTHER
40 Previous Clinical Trials
14,583 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
GastroenterologyJournal
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, Colleen R., Stacy Kahn, Purna Kashyap, Loren Laine, David Rubin, Ashish Atreja, Thomas Moore, and Gary Wu. 2015. “Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook”. Gastroenterology. Elsevier BV. doi:10.1053/j.gastro.2015.05.008.
Gut MicrobesJournal
High-throughput DNA Sequence Analysis Reveals Stable Engraftment of Gut Microbiota Following Transplantation of Previously Frozen Fecal Bacteria
Hamilton, Matthew J., Alexa R. Weingarden, Tatsuya Unno, Alexander Khoruts, and Michael J. Sadowsky. 2013. “High-throughput DNA Sequence Analysis Reveals Stable Engraftment of Gut Microbiota Following Transplantation of Previously Frozen Fecal Bacteria”. Gut Microbes. Informa UK Limited. doi:10.4161/gmic.23571.
GastroenterologyJournal
Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome
Vrieze, Anne, Els Van Nood, Frits Holleman, Jarkko Salojärvi, Ruud S. Kootte, Joep F.W.M. Bartelsman, Geesje M. Dallinga–Thie, et al.. 2012. “Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome”. Gastroenterology. Elsevier BV. doi:10.1053/j.gastro.2012.06.031.
clinicaltrials.govStudy
Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients
Johane Allard 2017. "Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02970877.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top